Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Implementation of a multidisciplinary infectious diseases team in a tertiary hospital within an Antimicrobial Stewardship Program.

Buyle FM, Wallaert M, Beck N, Boelens J, Callens S, Claeys G, Deryckere S, Haegeman E, Leroux-Roels I, Sermijn E, Steel E, Robays H, Vandekerckhove L, Vermis K, Vogelaers D.

Acta Clin Belg. 2014 Oct;69(5):320-6. doi: 10.1179/2295333714Y.0000000045. Epub 2014 Jul 16.

PMID:
25027808
2.

Development and validation of potential structure indicators for evaluating antimicrobial stewardship programmes in European hospitals.

Buyle FM, Metz-Gercek S, Mechtler R, Kern WV, Robays H, Vogelaers D, Struelens MJ; members of the Antibiotic Strategy International (ABS) Quality Indicators Team.

Eur J Clin Microbiol Infect Dis. 2013 Sep;32(9):1161-70. doi: 10.1007/s10096-013-1862-4. Epub 2013 Mar 23.

PMID:
23525773
3.

A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals.

Buyle FM, Decruyenaere J, De Waele J, Tulkens PM, Van Audenrode T, Depuydt P, Claeys G, Robays H, Vogelaers D.

Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):763-8. doi: 10.1007/s10096-012-1803-7. Epub 2012 Dec 28.

PMID:
23271675
4.

Prospective multicentre feasibility study of a quality of care indicator for intravenous to oral switch therapy with highly bioavailable antibiotics.

Buyle FM, Metz-Gercek S, Mechtler R, Kern WV, Robays H, Vogelaers D, Struelens MJ; Antibiotic Strategy International-ABS Quality Indicators Team.

J Antimicrob Chemother. 2012 Aug;67(8):2043-6. doi: 10.1093/jac/dks145. Epub 2012 May 7.

PMID:
22566589
5.

Epidemiology of infection in critically ill patients with acute renal failure.

Reynvoet E, Vandijck DM, Blot SI, Dhondt AW, De Waele JJ, Claus S, Buyle FM, Vanholder RC, Hoste EA.

Crit Care Med. 2009 Jul;37(7):2203-9. doi: 10.1097/CCM.0b013e3181a03961.

PMID:
19487937
6.

Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection.

Vandijck DM, Depaemelaere M, Labeau SO, Depuydt PO, Annemans L, Buyle FM, Oeyen S, Colpaert KE, Peleman RP, Blot SI, Decruyenaere JM.

Int J Antimicrob Agents. 2008 Feb;31(2):161-5. doi: 10.1016/j.ijantimicag.2007.10.015.

PMID:
18164599
7.

Infection risk related to the use of medicinal leeches.

Bauters TG, Buyle FM, Verschraegen G, Vermis K, Vogelaers D, Claeys G, Robays H.

Pharm World Sci. 2007 Jun;29(3):122-5. Epub 2007 Mar 13.

PMID:
17353971
8.

Antifungal drugs and rational use of antifungals in treating invasive aspergillosis: the role of the hospital pharmacist.

Bauters TG, Buyle FM, Peleman R, Robays H.

Pharm World Sci. 2005 Feb;27(1):31-4. Review.

PMID:
15861932

Supplemental Content

Loading ...
Support Center